Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

Phase 2 Terminated 112 enrolled University of Virginia National Institute of Neurological Disorders and Stroke (NINDS) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).

Timeline

Start: 2005-11
Primary completion: 2009-03
Completion: 2009-09

Publications

Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010 Apr;41(4):707-11. doi: 10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Alteplase	Protein / enzyme biologic	0.9 mg/kg	Intravenous
Comparator	Tenecteplase	Protein / enzyme biologic	0.1 mg/kg	Intravenous
Comparator	Tenecteplase	Protein / enzyme biologic	0.25 mg/kg	Intravenous
Comparator	Tenecteplase	Protein / enzyme biologic	0.4 mg/kg	Intravenous

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

Summary

Timeline

Publications

Drugs

Indications